Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma

Inclusion Criteria: * Refractory or recurrent retinoblastoma with vitreous seeding meeting eligibility criteria by ultrasonic biomicroscopy performed during examination under anesthesia (EUA) by an ophthalmologist: * At least three consecutive clock hours of disease-free, attached peripheral retina through which the intraocular injection may be administered. * Absence of invasion in anterior and posterior chamber. * Absence of anterior hyaloid detachment. * Absence of retinal detachment at the entry site. * Absence of tumor at the entry site. * ECOG Performance Score must be ≤ 2 within two weeks prior to registration. * Participants must have an adequate liver function, as defined by bilirubin ≤3 x upper limit of normal (ULN), and SGOT and SGPT ≤3 x ULN. * Participants must have adequate renal function as defined by serum creatinine ≤3 x ULN for age. * Legal guardians must sign an informed consent indicating that they are aware of this study, the possible benefits, and toxic side effects. Legal guardians will be given a signed copy of the consent form. Exclusion Criteria: * Presence of metastatic disease or gross orbital involvement. * Participants must not have an invasive infection at time of protocol entry. * Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.